Sugi Predict

Sugi Predict / Targets / AKR1C1

AKR1C1

Aldo-keto reductase family 1 member C1 · Q04828 · AKR1C1 on Sugi Atlas →

63,676 patent compounds predicted against AKR1C1, 43,520 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL184603 SCHEMBL184603 1.00 6/20
SCHEMBL39275 SCHEMBL39275 1.00 4/20
SCHEMBL181529 SCHEMBL181529 1.00 4/20
SCHEMBL123067 SCHEMBL123067 0.64 4/20
SCHEMBL164579 SCHEMBL164579 0.59 4/20
SCHEMBL164580 SCHEMBL164580 0.59 4/20
SCHEMBL165294 SCHEMBL165294 0.59 4/20
Biphenyl Biphenyl (SCHEMBL195288) 0.45 4/20
SCHEMBL122472 SCHEMBL122472 0.44 4/20
Mefenamic Acid Mefenamic Acid (SCHEMBL3544) 1.00 3/20
SCHEMBL80025 SCHEMBL80025 0.74 3/20
SCHEMBL2221 SCHEMBL2221 0.55 3/20
SCHEMBL156023 SCHEMBL156023 0.54 3/20
SCHEMBL68982 SCHEMBL68982 0.53 3/20
SCHEMBL156549 SCHEMBL156549 0.53 3/20
SCHEMBL49835 SCHEMBL49835 0.47 3/20
SCHEMBL152456 SCHEMBL152456 0.45 3/20
SCHEMBL38891 SCHEMBL38891 0.42 3/20
SCHEMBL39336 SCHEMBL39336 0.41 3/20
Indomethacin Indomethacin (SCHEMBL9300) 1.00 2/20

Clinical trials — most relevant to AKR1C1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Blood Pressure Regulation - Role of Potassium PHASE4COMPLETED
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer PHASE3COMPLETED
PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia PHASE1/PHASE2UNKNOWN
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris PHASE1/PHASE2UNKNOWN
Tolerability of Enteral NAC in Infants PHASE1NOT_YET_RECRUITING
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole nanWITHDRAWN
Tissue Predictors of Abiraterone Benefit nanCOMPLETED
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy nanRECRUITING
Adrenoleukodystrophy National Registry Study nanRECRUITING
ALDH2 Genetic Testing in East Asian Community nanNOT_YET_RECRUITING
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases nanCOMPLETED
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
A Study of Genetic Influence on LDL Hyper-responsiveness in Patients Following a Ketogenic Diet nanRECRUITING
Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China nanCOMPLETED
Individualized Antiretroviral Therapy nanCOMPLETED
Gene Polymorphisms Influencing Steroid Synthesis and Action nanWITHDRAWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH nanCOMPLETED
Final Height in Patients With CAH nanUNKNOWN
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC nanCOMPLETED
VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management nanUNKNOWN
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension nanUNKNOWN
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 nanCOMPLETED
Pharmacogenetic Determinants Of Treatment Response In Children nanRECRUITING
Genetic Association of Diabetic Retinopathy-1 nanUNKNOWN
The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2 nanUNKNOWN
Plant-based Diets and Body Weight and Selected Metabolic Parameters Management in Obese Patients. nanCOMPLETED
A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a AKR1C1 binder may also engage these)

ProteinNameSimilarity
AKR1C2 Aldo-keto reductase family 1 member C2 1.000 landscape →
Q5REQ0 — 1.000 Q5REQ0 →
AKR1C3 Aldo-keto reductase family 1 member C3 1.000 landscape →
Q5R7C9 — 1.000 Q5R7C9 →
Q95JH7 — 1.000 Q95JH7 →
Q95JH6 — 1.000 Q95JH6 →
Q6W8P9 — 1.000 Q6W8P9 →
Q1XAA8 — 0.999 Q1XAA8 →
Q95JH5 — 0.995 Q95JH5 →
P05980 — 0.994 P05980 →
P80508 — 0.993 P80508 →
P52898 — 0.993 P52898 →
AKR1C4 Aldo-keto reductase family 1 member C4 0.993 landscape →
Q95JH4 — 0.990 Q95JH4 →
P52897 — 0.988 P52897 →
P70694 — 0.986 P70694 →
D3ZF77 — 0.979 D3ZF77 →
Q91WR5 — 0.963 Q91WR5 →
Q5T2L2 — 0.957 Q5T2L2 →
Q6AYQ2 — 0.950 Q6AYQ2 →
Q8K023 — 0.948 Q8K023 →
Q6P8M1 — 0.940 Q6P8M1 →
P27119 — 0.940 P27119 →
Q9PTM4 — 0.940 Q9PTM4 →
P27118 — 0.940 P27118 →
P51652 — 0.940 P51652 →
P47727 — 0.939 P47727 →
P27117 — 0.938 P27117 →
Q8R4N0 — 0.938 Q8R4N0 →
B2GV72 — 0.938 B2GV72 →